Evaluation of Stat5 as a potential drug target in bcr/abl-induced leukemias by Hölbl, Andrea et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
BMC Pharmacology
Open Access Meeting abstract
Evaluation of Stat5 as a potential drug target in bcr/abl-induced 
leukemias
Andrea Hölbl1, Christian Schuster1, Boris Kovacic2, Maria Hölzl1, 
Sabine Fajmann1, Florian Grebien3, Lothar Hennighausen4, Yongzhi Cui4, 
Richard Moriggl5, Hartmut Beug2 and Veronika Sexl*1
Address: 1Centre of Biomolecular Medicine and Pharmacology, Medical University of Vienna, 1090 Vienna, Austria, 2Institute of Molecular 
Pathology (IMP), 1030 Vienna, Austria, 3Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM), 1090 Vienna, 
Austria, 4NIDDK, National Institute of Health, Bethesda, MD 20892, USA and 5Ludwig-Boltzmann Institute for Cancer Research (LBI-CR), 1090 
Vienna, Austria
Email: Veronika Sexl* - veronika.sexl@meduniwien.ac.at
* Corresponding author    
The Stat5 transcription factors Stat5a and Stat5b have
been implicated in lymphoid development and transfor-
mation. Using the complete Stat5 knockout mice, we have
previously shown that Stat5a/bnull/null cells were resistant to
transformation and leukemia development induced by
Abelson oncogenes, whereas Stat5a/bΔN/ΔN  cells readily
transformed. So far, these findings showed distinct sus-
ceptibility to Abelson-induced transformation of Stat5a/
bΔN/ΔN and Stat5a/bnull/null mice and defined Stat5 as key
regulator of initial transformation. In this study, we tested
whether Stat5a/b is also essential for the maintenance of
a transformed state. Therefore we developed a system,
where Stat5a/b could be deleted at will. Abelson-trans-
formed B lymphoid cells were generated from Stat5a/bfl/fl
gene targeted mice that had been crossed with Mx-Cre
transgenic animals. These leukemic Stat5a/bfl/flMxCre cells
were then used to test effects of Stat5a/b ablation in vitro
and in vivo. In vitro, Stat5a/b deletion resulted in a cell
cycle arrest followed by apoptosis. Nine days after dele-
tion, no viable cells could be detected. In line with that, a
down-regulation of Stat5 target genes mediating G1/S
transition within the cell cycle and viability, such as cyclin
D2 and cyclin D3, c-myc and bcl-xL was found. When
leukemic Stat5a/bfl/flMxCre cells were injected into wild
type or immuno-compromised mice leukemia rapidly
developed. Again, deletion of Stat5a/b in vivo within the
leukemic cells significantly counteracted disease progres-
sion as indicated by an increase of leukemia latency from
16 to 49 days. Eventually, all animals succumbed to a
Stat5a/b-positive leukemia indicating that a few residual
cells escaped deletion. Moreover, p53 abruption or over-
expression of the oncogene did not alter the susceptibility
to Stat5 loss of established leukemic cell lines. Taken
together our data define a key role for Stat5a/b not only
for lymphoid development but also for lymphoid trans-
formation. Stat5a/b is necessary for the initial transforma-
tion as well as for leukemia progression. This absolute
necessity for the proliferation and viability of Abelson-
transformed cells puts Stat5a/b into the spotlight of new
therapeutic strategies for the treatment of bcr/abl-induced
leukemias.
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